Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBX2660 Administered by Colonoscopy in Adults With Recurrent Clostridioides Difficile Infection
NCT05831189Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Apr 2023
- Primary completion
- Jan 2025
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 3 trial of RBX2660 in Clostridioides difficile infection (CDI), sponsored by Ferring Pharmaceuticals. Started Apr 2023; status: completed.
02
Drugs
RBX2660
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT05831189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05831189.